AARD Lead Plaintiff Deadline is Quickly Approaching - Robbins LLP Urges Aardvark Therapeutics, Inc. Stockholders to Contact the Firm for Information About Leading the Class Action

Robbins LLP is investigating allegations that Aardvark Therapeutics misled investors about the viability and efficacy of its lead drug candidate. The inquiry creates legal and reputational risk for the biotech company and may raise investor concerns over the candidate's clinical and commercial prospects.